Oral diabetes drug orforglipron shows superior blood sugar control in phase 3 trial
The GLP-1 receptor agonist outperformed dapagliflozin on glycaemic endpoints, though tolerability concerns persist.
Read the full articleYou might also wanna read
ACHIEVE results show A1C reduction, weight loss in type 2 diabetes
Investigators aim to use orforglipron to address the limitations of injectable GLP-1 RAs. The primary goal is to provide an alternative that
CU Anschutz Clinical Trial Tests Orforglipron, an Oral GLP-1 Pill as Alternative to Injectable Weight-Loss Drugs
Orforglipron is an FDA-approved non-peptide oral GLP-1 pill, an alternative to injectable weight-loss drugs. Demand for GLP-1s has surged, b
news.cuanschutz.edu·2d agoNew weight loss pill beats oral Ozempic in major trial
A new once-daily weight-loss pill called orforglipron delivered better weight loss and blood sugar improvements than the leading oral semagl
FDA Approves Foundayo (orforglipron): The First Oral GLP-1 Weight Loss Pill Without Fasting Requirements
FDA approved Foundayo (orforglipron) on April 1, 2026 — the only oral GLP-1 pill for weight loss you can take any time of day without fastin
GLP-1 Receptor Agonists Show Promise Against Obesity Related Cancer
The post GLP-1 Receptor Agonists Show Promise Against Obesity Related Cancer appeared first on European Medical Journal .
Oral small-molecule GLP-1 RA improves blood glucose and weight reduction
The VISTA and SOLSTICE phase 2b trials evaluated the use of the glucagon-like peptide-1 receptor agonist (GLP-1 RA) elecoglipron in adults.
Comments
Sign in to join the conversation.
No comments yet. Be the first.